Table 2 Adverse events
From: Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
MS-LAQ-101 % of patients Preferred term | Pooled placebo (n = 28) | Laquinimod 0.9 mg (n = 12) | Laquinimod 1.2 mg (n = 12) | Laquinimod 1.5 mg (n = 12) | Laquinimod 1.8 mg (n = 11) | Laquinimod 2.1 mg (n = 13) | Laquinimod 2.4 mg (n = 12) | Laquinimod 2.7 mg (n = 12) |
|---|---|---|---|---|---|---|---|---|
All | 96.4 | 75 | 100 | 83.3 | 90.9 | 92.3 | 100 | 100 |
Headache | 32.1 | 50 | 66.7 | 41.7 | 18.2 | 38.5 | 91.7 | 41.7 |
C-reactive protein increased | 7.1 | 16.7 | 16.7 | 8.3 | 0 | 7.7 | 8.3 | 33.3 |
Vomiting | 0 | 0 | 0 | 8.3 | 0 | 7.7 | 0 | 33.3 |
Abdominal pain upper | 10.7 | 0 | 16.7 | 8.3 | 9.1 | 7.7 | 33.3 | 25 |
Back pain | 0 | 16.7 | 0 | 16.7 | 0 | 7.7 | 25 | 25 |
Blood fibrinogen increased | 0 | 0 | 16.7 | 0 | 0 | 7.7 | 0 | 25 |
Myalgia | 0 | 0 | 0 | 0 | 9.1 | 0 | 8.3 | 25 |
Nausea | 7.1 | 8.3 | 0 | 8.3 | 0 | 7.7 | 25 | 25 |
Tension headache | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 |
Diarrhea | 7.1 | 8.3 | 8.3 | 8.3 | 9.1 | 15.4 | 8.3 | 16.7 |
Insomnia | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 16.7 |
Blood creatine Phosphokinase increased | 14.3 | 0 | 8.3 | 8.3 | 18.2 | 0 | 0 | 8.3 |
Nasopharyngitis | 10.7 | 16.7 | 33.3 | 8.3 | 0 | 38.5 | 8.3 | 8.3 |
Oropharyngeal pain | 0 | 0 | 0 | 0 | 18.2 | 0 | 0 | 8.3 |
Pain in extremity | 0 | 8.3 | 8.3 | 0 | 18.2 | 0 | 0 | 8.3 |
Dizziness | 10.7 | 0 | 8.3 | 0 | 9.1 | 0 | 25 | 0 |
Contusion | 0 | 0 | 0 | 0 | 0 | 7.7 | 16.7 | 0 |